Patisiran clinical trials
Also written ALN-TTR02 and ONPATTRO.
How each study uses patisiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 10 Aug 2018 · ONPATTRO · NDA 210922 (FDA, Drugs@FDA)
- European Union
- 27 Aug 2018 · Onpattro · EMEA/H/C/004699 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Alnylam Pharmaceuticals (8) · Austin Neuromuscular Center (1)
Studies
Open first, then newest update. How each study uses patisiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran TherapyCompletedEarly Phase 1Austin Neuromuscular CenterNCT05023889Written as patisiran
- APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)CompletedPhase 3Alnylam PharmaceuticalsNCT03997383Written as Patisiran
- APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisCompletedPhase 3Alnylam PharmaceuticalsNCT01960348Written as patisiran (ALN-TTR02)
- Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver TransplantCompletedPhase 3Alnylam PharmaceuticalsNCT03862807Written as Patisiran
- Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) AmyloidosisCompletedPhase 2Alnylam PharmaceuticalsNCT01617967Written as Patisiran
- The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)CompletedPhase 2Alnylam PharmaceuticalsNCT01961921Written as ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
- The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)CompletedPhase 3Alnylam PharmaceuticalsNCT02510261Written as Patisiran
- A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy VolunteersCompletedPhase 1Alnylam PharmaceuticalsNCT02053454Written as patisiran (ALN-TTR02)
- Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer SubjectsCompletedPhase 1Alnylam PharmaceuticalsNCT01559077Written as ALN-TTR02
Given beside what is tested · 1 — patisiran is usual care or a partner of the new treatment
Codes
What other systems call patisiran · ClinicalTrials.gg INT000438
- MeSH (NLM) C000606954patisiranConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 50FKX8CB2YPATISIRANConfirmed FDA, NLM
- RxNorm 2053490One source FDA
- NCI Thesaurus C116792PatisiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000606954 | patisiran | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 50FKX8CB2Y | PATISIRAN | Confirmed FDA, NLM |
| RxNorm | 2053490 | — | One source FDA |
| NCI Thesaurus | C116792 | Patisiran | One source FDA |
Also registered as patisiran sodium (UNII WO0YM16LKG · RxNorm 2053491).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.